New Statistical Method Provides Timely Comparative Effectiveness Research

Published Sep 17, 2012
Boston, MA, USA - Health care companies face increased pressure to compare the effectiveness of new treatments as early as possible. A study published in Value in Health reports on a novel statistical method that can be used to compare approved treatments even early in the product’s life cycle. Researchers at Analysis Group Inc., a health economic consultancy in Boston, MA, and at Shire Development LLC, in Wayne, PA, illustrate in their report how the method works. In their article, “Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research,” the authors discuss the application of this method in the areas of oncology, dermatology, diabetes, and attention-deficit hyperactivity disorder. While randomized head-to-head trials are the gold standard for comparing treatments, the new approach can provide indirect comparative evidence when such trials are not available. “The key is to fully leverage clinical trial data from pharmaceutical or device manufacturers,” says James Signorovitch, PhD, of Analysis Group, lead author of the article. Generally, clinical trials used to gain regulatory approval for new drugs or devices do not include comparisons of competing products. The study’s authors address this by using detailed patient data from the new product’s trials to match populations studied in published trials of competing products. Treatment outcomes are then evaluated between comparable populations. The article was sponsored by Shire Development LLC. Assistance with the writing of this press release was provided by Shire Development LLC.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health. For more information:

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now